Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;9(1):56-61.
doi: 10.2991/jegh.k.190225.002.

Pediatric Multidrug-resistant Tuberculosis in Kyiv City, Ukraine

Silvia Shinpei Chiang  1   2 , Yana Sheremeta  3 , Rachel Sophie Padilla  4 , Helen Elizabeth Jenkins  5 , Charles Robert Horsburgh Jr  6   7 , Vasyl Petrenko  3 , Natasha Renee Rybak  4   8
Affiliations

Pediatric Multidrug-resistant Tuberculosis in Kyiv City, Ukraine

Silvia Shinpei Chiang et al. J Epidemiol Glob Health. 2019 Mar.

Abstract

Few reports have described pediatric Multidrug-resistant Tuberculosis (MDR-TB) in the former Soviet republics, despite the fact that these countries have the highest proportion of TB cases that are MDR. We aimed to examine pediatric MDR-TB in Ukraine. This retrospective cohort study included all children <18 years of age who started undergoing MDR-TB treatment between January 1, 2011 and July 31, 2016 at Kyiv City Pediatric TB Hospital. From each child's clinical chart, we abstracted demographic and clinical data. Using Fisher's exact test, we compared characteristics between children with microbiologically confirmed vs. probable (i.e., clinically diagnosed) MDR-TB. The study population included 20 children with a median age of 5 years. At diagnosis, 12 (60%) had intrathoracic lymphadenopathy as their only radiographic abnormality, and two (10%) were asymptomatic. Children with confirmed MDR-TB were more likely to be adolescents or have radiologic abnormalities in addition to intrathoracic lymphadenopathy. Median treatment duration was 20 months. Eighteen (90%) children were treated successfully. The remaining two were transferred to another facility, and their final outcomes were unknown. The excellent outcomes in this cohort are consistent with high treatment success rates for pediatric MDR-TB reported in other parts of the world.

Keywords: Multidrug-resistant tuberculosis; Ukraine; adolescent; children.

PubMed Disclaimer

Conflict of interest statement

We have no conflicts of interest to declare.

References

    1. Jenkins HE, Tolman AW, Yuen CM, Parr JB, Keshavjee S, Pérez-Vélez CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet. 2014;383:1572–9. doi: 10.1016/s0140-6736(14)60195-1. - DOI - PMC - PubMed
    1. Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16:1193–201. doi: 10.1016/s1473-3099(16)30132-3. - DOI - PubMed
    1. Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med. 2018;15:e1002591. https://www.ncbi.nlm.nih.gov/pubmed/29995958. - PMC - PubMed
    1. Gegia M, Jenkins HE, Kalandadze I, Furin J. Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009–2011. Int J Tuberc Lung Dis. 2013;17:624–9. doi: 10.5588/ijtld.12.0792. - DOI - PMC - PubMed
    1. Smirnova PA, Turkova A, Nikishova EI, Seddon JA, Chappell E, Zolotaya OA, et al. Multidrug-resistant tuberculosis in children in northwest Russia: an observational cohort study. Eur Respir J. 2016;48:1496–9. doi: 10.1183/13993003.00354-2016. - DOI - PubMed

Substances

LinkOut - more resources